HealthValue
back to home page
HGF/SF
Mesenchymal
cells
Mitogenesis
Mutagenesis
Morphogenesis
CANCER
- oncogenesis
- metastasis
Epithelial cells
Endothelial cells
Hematopoietic cells
Neural cells
Melanocytes
Hepatocytes
c-Met
The fields of HGF/c-Met involvement
c-Met might well be one of the most important
membrane receptors.
Its ligand is HGF/SF. Activation of c-met in many cells (especially those listed to the right of the figure), plays a key role in :
- mitogenenesis
- motogenesis
- morphogenesis
AND in the development of CANCER, through
- oncogenesis
- metastatic process
Abbreviations :
HGF hepatocyte growth factor, SF scatter factor, c-Met mesenchymal epithelial transition factor
Fields of HGF/c-Met involvement
HGF/c-Met and cancer
Cancer therapies addressing HGF/c-Met
DISEASES
bird flu
cancer
diabetes
human growth hormone diseases
lysosomal diseases
mitochondrial diseases
multiple sclerosis
myelodysplastic sd
myopathies
osteoporosis
paroxysmal nocturnal hemoglobinuria
psoriasis
Cells/organelles
cell cycle
cells
chromosomes
DNA repair
exons
hemopoietic prog.
introns
lysosomes
mb. receptors
membrane CDs
mitochondria
proteasomes
stem cells
ABOUT MONOCLONALS
what is a monoclonal
chains & fragments
therapeutic fields
what are CDs
types of monoclonals
fusion proteins
cells to build monoclonals
making monoclonals
IgG1/IgG2 differences
F(ab) fragments
Fc fragment
Fc structure
Fc e receptors
BioTherapies
antisense
cell therapy
exon skipping
gene therapy
hemopoietic prog.
monoclonals
protein kinases
recombinant prot.
stem cells
Pathways
Adams
AKT
amino acids
complement
cancer pathways
cdk
c-Met
DPP IV
EGF
EGFRvIII
GPCR
G proteins
HGF
ILGF
kinome
Kras
mannose P
MET
NFKB
nucleotides
protein kinases
proteins
Ras
RET
sheddases
sunitinib/sorafenib
VEGF
Wnt
MONOCLONALS
abatacept
abciximab
adalimumab
alefacept
alemtuzumab
anti KDR
basiliximab
belatacept
bevacizumab
CDP 791
certolizumab
cetuximab
dacluzimab
denosumab
eculizumab
efalizumab
etanercept
IMC 1121
infliximab
ipilimumab
lumiliximab
Mab 806
mapatumumab
matuzumab
natalizumab
nimotuzumab
ocrelizumab
ofatumumab
omalizumab
palivizumab
panitumumab
ranibizumab
rituximab
ticilimumab
trastuzumab
VEGF Trap
zalutumumab